What Are the Main Threats to AbbVie's Humira?

AbbVie , which was spun out of health care stalwart Abbott Laboratories at the start of 2013, has beaten the market -- and its former parent company -- by leaps and bounds this year. It reported solid second-quarter results, largely fueled by 16% year-over-year sales growth of its top-selling autoimmune disease drug, Humira, but are there any threats to AbbVie's most important product? In the following video, from The Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso review the highlights from AbbVie's second-quarter results, discuss the company's dependence on its high-flying blockbuster drug, and explain potential competitive threats to Humira, such as Pfizer's drug Xeljanz.

AbbVie may be beating the market this year, but Motley Fool co-founder David Gardner, founder of the No. 1 growth stock newsletter in the world, has developed a unique strategy for uncovering truly wealth-changing stock picks. And he wants to share it, along with a few of his favorite growth stock superstars, WITH YOU! It's a special 100% FREE report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains... and click HERE for instant access to a whole new game plan of stock picks to help power your portfolio.

The article What Are the Main Threats to AbbVie's Humira? originally appeared on Fool.com.

David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Learn about investing from the comfort of your own home.

Portfolio Basics

Take the first steps to building your portfolio.

View Course »

Investment Strategies

Learn the strategies you need to build a winning portfolio

View Course »

Add a Comment

*0 / 3000 Character Maximum